Neurosteroids are essential endogenous compounds which modulate numerous brain-related functions. Neurosteroids affect both the excitatory (glutamate) and the inhibitory (γ-aminobutyric acid, GABA) systems in the brain allowing for the modulation of a wide array of emotions and behaviors. Their synthesis is increased in response to stress, helping the organism to return to homeostasis. Alterations of neurosteroid concentrations therefore have a role in the pathophysiology of stress and stress-related conditions, such as mood (therefore acting on sadness and anger) and anxiety (fear) disorders. Here, we summarize the action of some neuroactive compounds, such as allopregnanolone, pregnanolone, pregnenolone, pregnenolone sulfate and dehydroepiandrosterone, in regulating emotions and outline their current pharmacological use in different pathologies.
Citation: Flavia di Michele, Elena Romeo. What do we need to know about neurosteroids and emotions?[J]. AIMS Molecular Science, 2023, 10(2): 70-78. doi: 10.3934/molsci.2023006
Neurosteroids are essential endogenous compounds which modulate numerous brain-related functions. Neurosteroids affect both the excitatory (glutamate) and the inhibitory (γ-aminobutyric acid, GABA) systems in the brain allowing for the modulation of a wide array of emotions and behaviors. Their synthesis is increased in response to stress, helping the organism to return to homeostasis. Alterations of neurosteroid concentrations therefore have a role in the pathophysiology of stress and stress-related conditions, such as mood (therefore acting on sadness and anger) and anxiety (fear) disorders. Here, we summarize the action of some neuroactive compounds, such as allopregnanolone, pregnanolone, pregnenolone, pregnenolone sulfate and dehydroepiandrosterone, in regulating emotions and outline their current pharmacological use in different pathologies.
[1] | Panksepp J (2005) Affective neuroscience: the foundations of human and animal emotions.Oxford Univ Press. |
[2] | Damasio AR (1998) Emotion in the perspective of an integrated nervous system. Brain Research Brain Res Rev 26: 83-86. https://doi.org/10.1016/S0165-0173(97)00064-7 |
[3] | Ekman P, Davidson RJ (1994) The Nature of emotion: fundamental questions. New York: Oxford University Press 291-293. |
[4] | Cabanac M (2002) What is emotion?. Behav Processes 60: 69-83. https://doi.org/10.1016/S0376-6357(02)00078-5 |
[5] | Averill JR (1999) Individual Differences in Emotional Creativity: Structure and Correlates. J Personality 67: 331-371. https://doi.org/10.1111/1467-6494.00058 |
[6] | Pinker S (1997) How the mind works. New York: WW Norton & Company 342. |
[7] | Wilson TD, Dunn EW (2004) Self-knowledge: its limits, value, and potential for improvement. Ann Rev Psychol 55: 493-518. https://doi.org/10.1146/annurev.psych.55.090902.141954 |
[8] | Barrett LF, Mesquita B, Ochsner KN, et al. (2007) The experience of emotion. Ann Rev Psychol 58: 373-403. https://doi.org/10.1146/annurev.psych.58.110405.085709 |
[9] | Cannon WB (1927) The James-Lange theory of emotions: A critical examination and an alternative theory. Am J Psychol 39: 106-124. https://doi.org/10.2307/1415404 |
[10] | Bard P (1928) A diencephalic mechanism for the expression of rage with special reference to the sympathetic nervous system. Am J Physiol 84: 490-515. https://doi.org/10.1152/ajplegacy.1928.84.3.490 |
[11] | Agnati LF, Tiengo M, Ferraguti F, et al. (1991) Pain, analgesia, and stress: an integrated view. Clin J Pain 7: S23-37. https://doi.org/10.1097/00002508-199108000-00005 |
[12] | Selye H (1956) The Stress of Life.. New York, NY, USA: 5 McGraw-Hill. |
[13] | Coste SC, Murray SE, Stenzel-Poore MP (2001) Animal models of crh excess and crh receptor deficiency display altered adaptations to stress. Peptides 22: 733-741. https://doi.org/10.1016/S0196-9781(01)00386-2 |
[14] | Baulieu EE (1991) Neurosteroids: a new function in the brain. Biol Cell 71: 3-10. https://doi.org/10.1016/0248-4900(91)90045-O |
[15] | Paul SM, Purdy RH (1992) Neuroactive steroids. FASEB journal 6: 2311-2322. https://doi.org/10.1096/fasebj.6.6.1347506 |
[16] | Maksay G, Fodor L (2011) Differential effects of two major neurosteroids on cerebellar and cortical GABA(A) receptor binding and function. Eur J Pharmacol 650: 94-101. https://doi.org/10.1016/j.ejphar.2010.10.003 |
[17] | Majewska MD (1992) Neurosteroids: endogenous bimodal modulators of the GABAA receptor. Mechanism of action and physiological significance. Prog Neurobiol 38: 379-395. https://doi.org/10.1016/0301-0082(92)90025-A |
[18] | Boero G, Tyler RE, O'Buckley TK, et al. (2022) (3α,5α)3-Hydroxypregnan-20-one (3α,5α-THP) Regulation of the HPA Axis in the Context of Different Stressors and Sex. Biomolecules 12: 1134. https://doi.org/10.3390/biom12081134 |
[19] | di Michele F, Caltagirone C, Spalletta G (2008) Neurosteroid Perturbation and Neuropsychiatric Symptoms in Schizophrenia: From the Mechanisms to the Treatment.Springer, Dordrecht ed. https://doi.org/10.1007/978-1-4020-6854-6_16 |
[20] | Matsumoto K, Uzunova V, Pinna G, et al. (1999) Permissive role of brain allopregnanolone content in the regulation of pentobarbital-induced righting reflex loss. Neuropharmacol 38: 955-963. https://doi.org/10.1016/S0028-3908(99)00018-0 |
[21] | Matsumoto K, Nomura H, Murakami Y, et al. (2003) Long-term social isolation enhances picrotoxin seizure susceptibility in mice: up-regulatory role of endogenous brain allopregnanolone in GABAergic systems. Pharm Biochem Behav 75: 831-835. https://doi.org/10.1016/S0091-3057(03)00169-2 |
[22] | Pinna G, Uzunova V, Matsumoto K, et al. (2000) Brain allopregnanolone regulates the potency of the GABAA receptor agonist muscimol. Neuropharmacol 39: 440-448. https://doi.org/10.1016/S0028-3908(99)00149-5 |
[23] | Guidotti A, Dong E, Matsumoto K, et al. (2001) The socially-isolated mouse: a model to study the putative role of allopregnanolone and 5α-dihydroprogesterone in psychiatric disorders. Brain Res Rev 37: 110-115. https://doi.org/10.1016/S0165-0173(01)00129-1 |
[24] | Puia G, Mienville J-M, Matsumoto K, et al. (2003) On the putative physiological role of allopregnanolone on GABAA receptor function. Neuropharmacol 44: 49-55. https://doi.org/10.1016/S0028-3908(02)00341-6 |
[25] | Pinna G (2010) In a mouse model relevant for post-traumatic stress disorder, selective brain steroidogenic stimulants (SBSS) improve behavioral deficits by normalizing allopregnanolone biosynthesis. Behav Pharmacol 21: 438-450. doi: https://doi.org/10.1097/FBP.0b013e32833d8ba0 |
[26] | Maurice-Gélinas C, Deslauriers J, Monpays C, et al. (2018) The 5α-reductase inhibitor finasteride increases suicide-related aggressive behaviors and blocks clozapine-induced beneficial effects in an animal model of schizophrenia. Physiol Behav 191: 65-72. https://doi.org/10.1016/j.physbeh.2018.03.036 |
[27] | Mostallino MC, Sanna E, Concas A, et al. (2009) Plasticity and function of extrasynaptic GABA(A) receptors during pregnancy and after delivery. Psychoneuroendocrinol 34: S74-83. https://doi.org/10.1016/j.psyneuen.2009.06.013 |
[28] | Zhao C, Gammie SC (2014) Glutamate, GABA, and glutamine are synchronously upregulated in the mouse lateral septum during the postpartum period. Brain Res 1591: 53-62. https://doi.org/10.1016/j.brainres.2014.10.023 |
[29] | Strohle A, Romeo E, di Michele F, et al. (2003) Panic attacks shift GABAA receptor modulatory neuroactive steroid composition. Arch Gen Psychiatry 60: 161-168. https://doi.org/10.1001/archpsyc.60.2.161 |
[30] | Rasmusson AM, Pinna G, Paliwal P, et al. (2006) Decreased cerebrospinal fluid allopregnanolone levels in women with posttraumatic stress disorder. Biol Psychiatry 60: 704-713. https://doi.org/10.1016/j.biopsych.2006.03.026 |
[31] | Romeo E, Ströhle A, Spalletta G, et al. (1998) Effects of antidepressant treatment on neuroactive steroids in major depression. Am J Psychiatry 155: 910-913. https://doi.org/10.1176/ajp.155.7.910 |
[32] | Ströhle A, Romeo E, Hermann B, et al. (1999) Concentrations of 3α-reduced neuroactive steroids and their precursors in plasma of patients with major depression and after clinical recovery. Biol Psychiatry 45: 274-277. https://doi.org/10.1016/S0006-3223(98)00328-X |
[33] | Nappi RE, Petraglia F, Luisi S, et al. (2001) Serum allopregnanolone in women with postpartum “blues”. Obstet Gynecol 97: 77-80. https://doi.org/10.1097/00006250-200101000-00016 |
[34] | Rapkin AJ, Morgan M, Goldman L, et al. (1997) Progesterone metabolite allopregnanolone in women with premenstrual syndrome. Obstet Gynecol 90: 709-714. https://doi.org/10.1097/00006250-200101000-00016 |
[35] | Spalletta E, Romeo G, Bonaviri G, et al. (2005) Preliminary evidence for association between aggression, hostility and 5alpha-3alpha-tetrahydroprogesterone levels in schizophrenia. J Psychiatry Neurosci 30: 49-52. |
[36] | Marx CE, Keefe RS, Buchanan RW, et al. (2009) Proof-of-concept trial with the neurosteroid pregnenolone targeting cognitive and negative symptoms in schizophrenia. Neuropsycopharmacol 34: 1885-1903. https://doi.org/10.1038/npp.2009.26 |
[37] | Uzunova V, Sheline Y, Davis JM, et al. (1998) Increase in the cerebrospinal fluid content of neurosteroids in patients with unipolar major depression who are receiving fluoxetine or fluvoxamine. Proc Natl Acad Sci USA 95: 3239-3244. https://doi.org/10.1073/pnas.95.6.3239 |
[38] | Eser D, Schüle C, Baghai TC, et al. (2006) Neuroactive steroids in depression and anxiety disorders: clinical studies. Neuroendocrinol 84: 244-254. https://doi.org/10.1159/000097879 |
[39] | Uzunova V, Sampson L, Uzunov DP (2006) Relevance of endogenous 3α-reduced neurosteroids to depression and antidepressant action. Psychopharmacol 186: 351-361. https://doi.org/10.1007/s00213-005-0201-6 |
[40] | Pinna G, Costa E, Guidotti A (2006) Fluoxetine and norfluoxetine stereospecifically and selectively increase brain neurosteroid content at doses that are inactive on 5-HT reuptake. Psychopharmacol 186: 362-372. https://doi.org/10.1007/s00213-005-0213-2 |
[41] | Osborne LM, Gispen F, Sanyal A, et al. (2017) Lower allopregnanolone during pregnancy predicts postpartum depression: an exploratory study. Psychoneuroendocrinol 79: 116-121. https://doi.org/10.1016/j.psyneuen.2017.02.012 |
[42] | Trivisano M, Lucchi C, Rustichelli C, et al. (2017) Reduced steroidogenesis in patients with PCDH19-female limited epilepsy. Epilepsia 58: e91-e95. https://doi.org/10.1111/epi.13772 |
[43] | Bloch M, Schmidt PJ, Danaceau M, et al. (2000) Effects of gonadal steroids in women with a history of postpartum depression. Am J Psychiatry 157: 924-930. https://doi.org/10.1176/appi.ajp.157.6.924 |
[44] | Deligiannidis KM, Kroll-Desrosiers AR, Mo S, et al. (2016) Peripartum neuroactive steroid and γ-aminobutyric acid profiles in women at-risk for postpartum depression. Psychoneuroendocrinol 70: 98-107. https://doi.org/10.1016/j.psyneuen.2016.05.010 |
[45] | Stárka L, Dušková M, Hill M (2015) Dehydroepiandrosterone: a neuroactive steroid. J Steroid Biochem Mol Biol 145: 254-260. https://doi.org/10.1016/j.jsbmb.2014.03.008 |
[46] | Rasmusson AM, King MW, Valovski I, et al. (2019) Relationships between cerebrospinal fluid GABAergic neurosteroid levels and symptom severity in men with PTSD. Psychoneuroendocrinol 102: 95-104. https://doi.org/10.1016/j.psyneuen.2018.11.027 |
[47] | Marx CE, Bradford DW, Hamer RM, et al. (2011) Pregnenolone as a novel therapeutic candidate in schizophrenia: emerging preclinical and clinical evidence. Neuroscience 191: 78-90. https://doi.org/10.1016/j.neuroscience.2011.06.076 |
[48] | Ritsner MS, Gibel A, Shleifer T, et al. (2010) Pregnenolone and dehydroepiandrosterone as an adjunctive treatment in schizophrenia and schizoaffective disorder: an 8-week, double-blind, randomized, controlled, 2-center, parallel-group trial. J Clin Psychiatry 71: 1351-1362. https://doi.org/10.4088/JCP.09m05031yel |
[49] | Dazzi L, Seu E, Cherchi G, et al. (2004) Inhibition of stress-induced dopamine output in the rat prefrontal cortex by chronic treatment with olanzapine. Biol Psychiatry 55: 477-483. https://doi.org/10.1016/j.biopsych.2003.11.020 |
[50] | Powell JG, Garland S, Preston K, et al. (2020) Brexanolone (Zulresso): Finally, an FDA-Approved Treatment for Postpartum Depression. Ann Pharmacother 54: 157-163. https://doi.org/10.1177/1060028019873320 |
[51] | Zheng W, Cai DB, Zheng W, et al. (2019) Brexanolone for postpartum depression: A meta-analysis of randomized controlled studies. Psychiatry Res 279: 83-89. https://doi.org/10.1016/j.psychres.2019.07.006 |
[52] | Kanes S, Colquhoun H, Gunduz-Bruce H, et al. (2017) Brexanolone (SAGE-547 injection) in post-partum depression: a randomised controlled trial. Lancet 390: 480-489. https://doi.org/10.1016/S0140-6736(17)31264-3 |
[53] | Hutcherson TC, Cieri-Hutcherson NE, Gosciak MF (2020) Brexanolone for postpartum depression. Am J Health Syst Pharm 77: 336-345. https://doi.org/10.1093/ajhp/zxz333 |
[54] | Lattanzi S, Riva A, Striano P (2021) Ganaxolone treatment for epilepsy patients: from pharmacology to place in therapy. Expert Rev Neurother 21: 1317-1332. https://doi.org/10.1080/14737175.2021.1904895 |